FINNENCE ▪ THE WIRE FILE
THE WIRE · № 70986
News■ Unclear/unknown
Vinci Pharmaceuticals Inc. Closes More Than $8 Million Series A Financing to Advance EPIPLANT™ Drug Delivery Platform
KINDNews
DIRECTION■ Unclear/unknown
SOURCES2
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-08 12:13 UTC
LAST UPDATE2026-10-08 12:13 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A private Series A for a drug-delivery platform is not accessible to public investors.
Private biotech financing, no listed exposure
CATALYST TO WATCH
First-in-human study initiation
MAIN RISK
Pre-clinical stage, private, unlisted
FULL DISPATCH
Key Takeaways Combined with its Seed round of $8.5M, the company has raised more than $16.5M in support of its activities. Vinci Pharmaceuticals closed an $8+ million Series A financing round to support manufacturing, testing/release activities and first-in-human studies of its EPIPLANT™...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Psilera Greenlit to Initiate Phase 2 of NIH Grant for Alcohol Use Disorder2026-10-08 12:15 UTC
Psilera Greenlit to Initiate Phase 2 of NIH Grant for Alcohol Use Disorder2026-10-08 12:15 UTC
→CORRELATIONshares Healthcare
GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution2026-10-08 12:30 UTC
GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution2026-10-08 12:30 UTC
←CORRELATIONshares Healthcare
Nuevocor Doses First Patient in SUNBEAM-LMNA Phase 1/2 Trial and Receives FDA Fast Track Designation for NVC-001 in LMNA Dilated Cardiomyopathy2026-10-08 11:30 UTC
Nuevocor Doses First Patient in SUNBEAM-LMNA Phase 1/2 Trial and Receives FDA Fast Track Designation for NVC-001 in LMNA Dilated Cardiomyopathy2026-10-08 11:30 UTC
←CORRELATIONshares Healthcare
Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology2026-10-08 11:30 UTC
Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology2026-10-08 11:30 UTC
←CORRELATIONshares Healthcare
Aragen Life Sciences begins Operations at OneHP, an Integrated High-potency Platform in Hyderabad, India2026-10-08 11:30 UTC
Aragen Life Sciences begins Operations at OneHP, an Integrated High-potency Platform in Hyderabad, India2026-10-08 11:30 UTC
←CORRELATIONshares Healthcare
Keenova Announces New Presentations at the Sexual Medicine Society of North America Annual Meeting2026-10-08 11:30 UTC
Keenova Announces New Presentations at the Sexual Medicine Society of North America Annual Meeting2026-10-08 11:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.